Kane Biotech Restarts Commercial Activities and Strengthens North American Management
MWN-AI** Summary
Kane Biotech Inc. (TSX-V:KNE) announced on February 12, 2026, a significant revival of its commercial operations for the revyve® Antimicrobial Wound Gel product line in North America. The company has received FDA 510(k) clearance and Health Canada approval for its revyve products, which address critical issues related to biofilm formation in wounds, a leading contributor to antibiotic resistance.
To initiate its market relaunch, Kane has established non-exclusive distribution agreements with Medstream Healthcare Solutions and Patient Care Medical in the United States, with immediate shipments anticipated. In Canada, Kane is revitalizing its relationship with Best Buy Medical Canada to a non-exclusive agreement and is rolling out targeted sales initiatives. Although initial sales figures remain modest, this represents a crucial step toward reactivating Kane's commercial momentum, as emphasized by Interim CEO Dr. Robert Huizinga.
Furthermore, to facilitate this renewed growth phase, Kane Biotech has strengthened its management team by appointing two seasoned industry veterans to the roles of Vice Presidents of Business Development. Sherida (Kay) Watkins Weaver will spearhead U.S. operations, bringing over 20 years of experience in wound care commercialization from previous roles at Omeza and Relevate Health. Patti Burke-Martin will lead initiatives in Canada, drawing on her expertise from EO2 Concepts, Coloplast, and ConvaTec. Dr. Huizinga highlighted the critical role their leadership will play in expanding the distribution network and promoting the adoption of revyve products.
Kane Biotech continues to focus on developing innovative wound care solutions that have the potential to transform healing outcomes while addressing critical healthcare challenges such as antibiotic resistance.
MWN-AI** Analysis
Kane Biotech Inc. (TSX-V: KNE) presents a compelling investment opportunity as it embarks on the resumption of its commercial activities for the revyve® Antimicrobial Wound Gel product line. This strategic move demonstrates the company’s proactive approach to reinvigorating its market presence in North America.
The recent appointment of Sherida (Kay) Watkins Weaver and Patti Burke-Martin as Vice Presidents of Business Development in the U.S. and Canada, respectively, adds significant value to Kane's management team. Both bring extensive industry experience and proven track records in wound care commercialization, which is crucial for executing effective market penetration strategies. Their established relationships could enhance distribution partnerships and drive product adoption in an important sector that increasingly demands effective wound care solutions.
Although current sales figures are modest, the agreements with Medstream Healthcare Solutions and Patient Care Medical demonstrate a foundational step towards scaling operations. Given that revyve® is FDA-cleared and Health Canada approved, it has regulatory backing that could ease market entry, while the effective management of biofilms it offers positions the product as a vital alternative in wound healing, especially in light of rising antibiotic resistance.
Investors should closely monitor developments in Kane Biotech’s commercial activities and execution of its growth plans. The company's strategy, focusing on generating scientific credibility and clinical validation, indicates a methodical approach to building a sustainable revenue model. However, it’s important to remain vigilant about potential risks, including the company’s reliance on equity financing and dependency on regulatory approvals.
In conclusion, Kane Biotech's recent actions suggest a recovery path with significant upside potential, making it worth considering for those looking to invest in innovative healthcare solutions. It is advisable to stay updated on the company’s progress and broader market trends influencing the wound care industry.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces the resumption of commercial activities in both the United States and Canada for its revyve® Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America.
US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray
Commercial Restart in the U.S. and Canada:
In the U.S., Kane has signed non-exclusive distribution/sales agreements with Medstream Healthcare Solutions, LLC (Dorval, FL) and Patient Care Medical (Austin, TX) with initial shipments expected in the near term.
In Canada, Kane has resumed commercial activity by converting its distribution agreement with Best Buy Medical Canada to a non-exclusive arrangement, along with targeted sales and sampling initiatives. While sales to date in both countries are not material, they mark a meaningful restart of Kane’s commercial engine.
“We are executing on our commitment to reset Kane Biotech using a disciplined market approach,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “We will continue to generate scientific credibility, clinical validation and with that, the commercial infrastructure.”
Strategic Management Appointments:
To support this next phase of growth, Kane has appointed two Vice Presidents of Business Development:
- Sherida (Kay) Watkins Weaver, Vice President of Business Development, United States. Kay brings over 20 years of experience in wound care commercialization, including leadership roles at Omeza and Relevate Health. She has led market access, reimbursement, and adoption strategies across health systems, long-term care, and home health markets.
- Patti Burke-Martin, Vice President of Business Development, Canada. Patti is a national wound care leader with senior roles at EO2 Concepts, Coloplast, and ConvaTec. She has a proven track record in building high-performing teams and driving adoption of advanced wound care technologies across Canada.
“Kay and Patti bring deep expertise and trusted relationships in their respective markets,” added Dr. Huizinga. “Their leadership will be instrumental as we expand our distribution network and support the growing adoption of revyve.”
About Kane Biotech Inc. (TSX-V:KNE)
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria. revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray are U.S. FDA 510(k) cleared. revyve® Antimicrobial Wound Gel is also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.
Join Kane’s Distribution List & Social Media:
To stay informed on the latest developments, sign up for the Company’s email distribution list HERE.
Follow Kane
Website: kanebiotech.com
LinkedIn: https://www.linkedin.com/company/kanebiotech/
Presentations: https://kanebiotech.com/publications-posters/
| For more information: | |
| Dr. Robert Huizinga Interim CEO Kane Biotech Inc. rhuizinga@kanebiotech.com (780) 970-1100 | Ray Dupuis Chief Financial Officer Kane Biotech Inc. rdupuis@kanebiotech.com (204) 298-2200 |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c571cd78-61af-4117-9a20-7a506a64ae40
FAQ**
How does the resumption of commercial activities for Kane Biotech Inc. KNBIF in the U.S. and Canada impact its financial outlook and revenue generation potential moving forward?
What strategies is Kane Biotech Inc. KNBIF implementing to enhance market adoption and sales of its revyve® Antimicrobial Wound Gel products across North America?
How do the newly appointed Vice Presidents of Business Development at Kane Biotech Inc. KNBIF plan to leverage their experience in wound care commercialization to benefit the company's growth?
What are the specific challenges Kane Biotech Inc. KNBIF anticipates in scaling its operations and achieving market acceptance for its wound care products in the competitive healthcare landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Kane Biotech Inc. (TSXVC: KNE:CC).
NASDAQ: KNE:CC
KNE:CC Trading
-5.0% G/L:
$0.095 Last:
12,000 Volume:
$0.10 Open:
